SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Julian who wrote (971)7/28/2000 12:40:26 PM
From: Garth Richmond  Respond to of 1321
 
EU Commission Approves Visudyne For The Treatment of Wet AMD in the European Union

"Visudyne therapy is the first approved drug treatment for this devastating condition. Now with approval throughout the European Union, Visudyne will provide new hope to many of the approximately 200,000 patients in the European Union who lose their vision from wet AMD every year," said Luzi von Bidder, President of CIBA Vision's worldwide Ophthalmics
Business Unit. "This much needed therapy will be available to eye care professionals and their patients across the European Union within the next few weeks."

biz.yahoo.com



To: Julian who wrote (971)7/31/2000 9:12:26 AM
From: Ian@SI  Read Replies (1) | Respond to of 1321
 
Julian,

What do you say we split the difference.

I've got them for tomorrow, August 1st for reporting earnings.

And finally AHH recognized that QLT just might have some potential...

Adams, Harkness & Hill upgraded QLT Inc (QLTI) to an "Accumulate"
rating from "Market Performer," following the European Union's
approval of the company's Visudyne eye treatment.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News